Signal from the log
Coultreon Biopharma
125 M$ · Series A · Belgium · Biotech
Biotech belge qui développe COL-5671, un inhibiteur oral de SIK3 conçu pour rééquilibrer l'inflammation chronique au lieu de la supprimer, ce qui est le pari inverse de la plupart des immunosuppresseurs. Elle vise le psoriasis et la rectocolite hémorragique, avec une preuve de concept attendue en 2027.
Verified
Announced on , logged by the watch of 12 August 2026.
- Operation
- Funding round
- Announced amount
- 125 M$
- Stage
- Series A
- Country
- Belgium
- Sector
- Biotech
What the log says
Editorial note, in French
Communiqué ouvert, montant relu et fonds nommés.
The investors
Led by Sofinnova Investments , Forbion , Novo Holdings , with Regeneron Ventures , Balyasny Asset Management , Galapagos , Luma Group , Samsara BioCapital , Longwood Fund , Finchley Healthcare Ventures
Provenance
Source longevity
Logged on 12 August 2026
Description Written in French during the watch run. Written during the watch run, after reading the issuer's press release or the source article.
Verification Amounts and fund names were double checked against the issuer's press release or an official filing.
What this status means
Verified The press release was opened: amount double checked, funds named. The article remains to be written.
The rule A signal is never removed from the log. A round set aside stays readable with its reason, because a collection you cannot reread is a collection you cannot correct.